Technology Bundle ID
TAB-2779

Multivalent, Multiple-Antigenic-Peptides for Serological Detection of HIV-1 Groups -M, -N, -O, and HIV-2

Linked ID
E-604-2013-0
Co-Inventors
Chou-Pong Pau (CDC)
Development Stages
Pre-Clinical (in vitro)
Development Status
In vitro data available
ICs
CDC
This CDC-developed invention pertains to multivalent antigenic peptides (MAPs) that can be used in a variety of HIV/AIDS diagnostics. There are two types of HIV: HIV-1 and HIV-2. HIV-1 is subdivided into groups M, N, and O, while HIV-2 is subdivided into subtypes A and B. Within HIV -1 group M, several different subtypes and numerous forms of recombinant viruses exist. To detect all types, groups, and subtypes of HIV by serological methods, a mixture of antigens derived from different viral strains representing different HIV types and subtypes is needed. However, due to the competition and dilution effect, mixing multiple antigens may reduce the amount of individual antigen bound to the solid phase and lead to a reduction in assay sensitivity.

It is known that MAPs, which contain multiple branches of an oligopeptide sequence, are more antigenic than the corresponding single chain linear peptides. The MAPs encompassed by this technology contain multiple branches of oligopeptides of different sequences, derived from HIV-1 group M, N, O, and HIV-2. Thus, depending on the peptide sequences incorporated, a single MAP can be used to detect HIV-1 group M alone, HIV-2 alone, or to simultaneously detect HIV-1 groups M, N, O, and HIV-2 with high sensitivity and specificity.
Commercial Applications
  • Diagnostic test for HIV-1 and/or HIV-2 infection
  • Blood and plasma donation screening
  • HIV/AIDS surveillance and monitoring programs
Competitive Advantages
  • Lateral flow assays for HIV detection and discrimination
  • On-site, point-of-care testing and diagnosis
  • Easily formulated as an ELISA kit for commercial or research applications
  • Technology can be used to develop a rapid, low-cost method of determining HIV status for home-use or low-resource settings

Request More Info

Licensing Contact:
Jeremiah David Mitzelfelt
jeremiah.mitzelfelt@nih.gov
Phone: 301-443-8518

Intellectual Properties

  • EIR Application
  • Research Tool – Patent protection is not being pursued for this technology.

Publications

Related Inventions

  • A Diagnostic Kit For Assessing Exposure Or Infection By The Koala Family Of Gammaretroviruses [E-053-2013-0]
  • A Simple Assay For Detecting Recent HIV-1 Infection And Estimating Incidence [E-555-2013-0]
  • Compositions And Methods For Rapid Detection Of HIV By Loop-Mediated Isothermal Amplification (LAMP) [E-173-2013-0]
  • DEVELOPMENT OF A CHIMERIC RECOMBINANT HIV-1 ENVELOPE PROTEIN DERIVED FROM IMMUNODOMINANT REGION (IDR) OF MULTIPLE SUBTYPES [E-358-2013-0]
  • DEVELOPMENT OF A RAPID HIV DIAGNOSTIC ASSAY FOR DIAGNOSIS AND DETECTION OF RECENT AND LONG TERM HIV-1 INFECTION [E-357-2013-0]
  • Development Of A New One-well Limiting-antigen Avidity Enzyme Immunoassay (LAg Avidity-EIA) To Detect Recent HIV I Infection Using A Multi-subtype Recombinant Protein, RIDR-M [E-522-2013-0]
  • Double-stranded Primers For The Detection And Quantification Of HIV -1 Nucleic Acids Using Polymerase Chain Reaction [E-638-2013-0]
  • HIV-1 GENOTYPING ASSAY FOR GLOBAL SURVEILLANCE OF HIV-1 DRUG RESISTANCE [E-259-2013-0]
  • Multiple Antigenic Peptide Assay For Detection Of HIV Or SIV Type Retroviruses [E-294-2013-0]
  • NUCLEIC ACIDS FOR DETECTING ASPERGILLUS SPECIES (I-016-96, I-016-96/0) [E-232-2013-0]
  • Use Of Argon As A Tissue Fixation Preservative [E-052-2013-0]

Collaborations

  • Licensing Desired
Date Published
Data Source
tts
Data Source ID
TAB-2779